EFFECT OF CO2 ON SUSCEPTIBILITIES OF ANAEROBES TO ERYTHROMYCIN, AZITHROMYCIN, CLARITHROMYCIN, AND ROXITHROMYCIN

被引:26
作者
SPANGLER, SK
JACOBS, MR
APPELBAUM, PC
机构
[1] HERSHEY MED CTR,DEPT PATHOL CLIN MICROBIOL,HERSHEY,PA 17033
[2] CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106
关键词
D O I
10.1128/AAC.38.2.211
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Oxyrase agar dilution method (Oxyrase, Inc., Mansfield, Ohio), which provides an anaerobic environment without added CO2, was compared with the reference agar dilution method recommended by the National Committee for Clinical Laboratory Standards (anaerobic chamber with 10% CO2) to test the susceptibilities of 302 gram-negative and gram-positive anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. For erythromycin, the overall MIC for 50% of isolates tested (MIC(50)) was 0.5 mu g/ml and the MIC(90) was 8.0 mu g/ml by the Oxyrase method, whereas they were 4.0 and 64.0 mu g/ml, respectively, under standard anaerobic conditions with CO2. At a breakpoint of 4.0 mu g/ml, 88% of strains were susceptible to erythromycin by the Oxyrase method, whereas 63% were susceptible in the chamber. The corresponding MIC(50)s and MIC(90)s of azithromycin, clarithromycin, and roxithromycin by the Oxyrase method were 0.5 and 8.0, 0.25 and 4.0, and 0.5 and 16.0 mu g/ml, respectively, whereas in the chamber they were 4.0 and >64.0, 2.0 and 64.0, and 2.0 and 64.0 mu g/ml, respectively. At a breakpoint of 8.0 mu g/ml for these three drugs, 89, 92, and 85% of the isolates, respectively, were susceptible by the Oxyrase method, whereas 67%, 72, and 68% of the isolates, respectively, were susceptible in the chamber. Most strains resistant to all four compounds by both methods were Bacteroides distasonis, Fusobacterium mortiferum, Fusobacterium varium and non-Clostridium perfringens Clostridium species. Results of the study may lead to a reappraisal of the role played by macrolides and azalides in the treatment of anaerobic infections.
引用
收藏
页码:211 / 216
页数:6
相关论文
共 42 条
[1]   ROXITHROMYCIN IN SKIN AND SOFT-TISSUE INFECTIONS [J].
AGACHE, P ;
AMBLARD, P ;
MOULIN, G ;
BARRIERE, H ;
TEXIER, L ;
BEYLOT, C ;
BERGOEND, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 :153-156
[2]   INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
JONES, RN ;
THORNSBERRY, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) :752-754
[3]   INFLUENCE OF THE TEST MEDIUM ON AZITHROMYCIN AND ERYTHROMYCIN REGRESSION STATISTICS [J].
BARRY, AL ;
FUCHS, PC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (10) :846-849
[4]   INVITRO POTENCY OF AZITHROMYCIN AGAINST GRAM-NEGATIVE BACILLI IS METHOD-DEPENDENT [J].
BARRY, AL ;
FUCHS, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (04) :607-610
[5]   TISSUE DISTRIBUTION OF ROXITHROMYCIN [J].
BERGOGNEBEREZIN, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 :113-120
[6]  
COPELAND J, 1991, COMMUNICATION
[8]  
ELIOPOULOS GM, 1988, J ANTIMICROB CHEMOTH, V21, P671
[9]   INVITRO AND INVIVO EVALUATION OF A-56268 (TE-031), A NEW MACROLIDE [J].
FERNANDES, PB ;
BAILER, R ;
SWANSON, R ;
HANSON, CW ;
MCDONALD, E ;
RAMER, N ;
HARDY, D ;
SHIPKOWITZ, N ;
BOWER, RR ;
GADE, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (06) :865-873
[10]   THE PHARMACOKINETICS OF AZITHROMYCIN IN HUMAN SERUM AND TISSUES [J].
FOULDS, G ;
SHEPARD, RM ;
JOHNSON, RB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 :73-82